Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 5—May 2004
Research

Multidrug-resistant Tuberculosis in Central Asia

Helen Suzanne Cox*Comments to Author , Juan Daniel Orozco*, Roy Male*, Sabine Ruesch-Gerdes†, Dennis Falzon*, Ian Small*, Darebay Doshetov‡, Yared Kebede§, and Mohammed Aziz¶
Author affiliations: *Médecins Sans Frontières Aral Sea Area Programme, Uzbekistan and Turkmenistan, Tashkent, Uzbekistan; †National Reference Centre for Mycobacteria, Borstel, Germany; ‡Ministry of Health, Nukus, Karakalpakstan, Uzbekistan; §Médecins Sans Frontières, Amsterdam, the Netherlands; ¶World Health Organization, Geneva, Switzerland

Main Article

Table 1

Key characteristics of the two regions and countries included in the surveya

Uzbekistan Turkmenistan
Population (6) 25,256,000 4,834,000
GDP per capita (6) U.S.$ 2,333 U.S.$ 5,269
Health expenditure per capita (6) U.S.$ 86 U.S.$ 286
Estimated TB incidence rate (all cases) (7) 92/100,000/y 84/100,000/y
Estimated smear-positive case detection (7) 44% 68%
Karakalpakstan Dashoguz
Population (2001 estimated)b 1,549,761 1,041,372
DOTS implementation 1998 (pilot districts)–2003 (full coverage) 2000 (pilot districts)–2002 (full coverage)
DOTS case notification rate (all cases) 482/100,000/y 213/100,000/y
DOTS case notification rate (smear- positive cases) 192/100,000/y 89/100,000/y
% of smear-positive cases previously treated (2002) 55 53
Success rate (new smear-positive cases registered in 2001) 68% 82%

aGDP, gross domestic product; TB, tuberculosis; DOTS, directly observed treatment strategy.

bSource: ministries of health in each region.

Main Article

References
  1. Farmer  PE, Kononets  AS, Borisov  SE, Goldfarb  A, Healing  T, McKee  M. Recrudescent tuberculosis in the Russian Federation. In: Farmer P, Kim J, editors. The global impact of drug-resistant tuberculosis. Boston: Harvard Medical School and the Open Society Institute; 1999.
  2. Espinal  MA, Laszlo  A, Simonsen  L, Boulahbal  F, Kim  SJ, Reniero  A, Global trends in resistance to anti-tuberculosis drugs. N Engl J Med. 2001;344:1294303. DOIPubMed
  3. World Health Organization. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. WHO/TB/97.229. Geneva: The Organization; 1997.
  4. Small  I, van der Meer  J, Upshur  REG. Acting on an environmental disaster: the case of the Aral Sea. Environ Health Perspect. 2001;109:5479. DOIPubMed
  5. World Health Organization. Managing tuberculosis at district level. A training course. Geneva: The Organization; 1994.
  6. World Health Organization. Country profiles for Uzbekistan and Turkmenistan. [accessed 18 Nov 2003]. Available from: http://www.who.int/country/uzb/en/
  7. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO Report 2003. Geneva: The Organization; 2003. WHO/CDS/TB/2003.316 Reprint. Available from: www.who.int/gtb/publications/globrep/index.html
  8. World Health Organization and the International Union Against Tuberculosis and Lung Disease. Guidelines for the surveillance in drug-resistant tuberculosis. Geneva: The Organization;1997. WHO/TB/96.216.
  9. Kent  PT, Kubica  GP. Public health mycobacteriology. A guide for the level III laboratory. Atlanta: Centers for Disease Control; 1985.
  10. Tsogt  G, Naranabt  N, Buyankhisig  B, Batkhuyag  B, Fujiki  A, Mori  T. The nationwide tuberculosis drug resistance survey in Mongolia, 1999. Int J Tuberc Lung Dis. 2002;6:28994.PubMed
  11. Results from DOTS-Plus pilot program. Data presented at the WHO DOTS-Plus Working Group Meeting, Paris, October 2003.
  12. McKee  M, Figueras  J, Chenet  L. Health sector reform in the former soviet republics of central Asia. Int J Health Plann Manage. 1998;13:13147. DOIPubMed
  13. The Economist Intelligence Unit. Country Report. Uzbekistan; 2002. [?]
  14. The European Observatory on Health Care Systems. In: Health care in Central Asia. McKee M, Healy J, Falkingham J, editors. Buckingham, UK: Open University Press; 2002. p. 179–93.
  15. Kimerling  ME, Kluge  H, Vezhnina  N, Iacovazzi  T, Demeulenaere  T, Portaels  F, Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis. 1999;3:4513.PubMed
  16. United Nations High Commissioner for Refugees. Central Asia on the move. Refugees Magazine 1996 May. Available from: http://www.unhcr.ch/cgi-bin/texis/vtx/
  17. Toungoussova  OS, Caugant  DA, Sandven  P, Mariandyshev  AO, Bjune  G. Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia. Int J Tuberc Lung Dis. 2002;6:40614.PubMed
  18. Lockman  S, Kruuner  A, Binkin  J, Levina  K, Wang  YC, Danilovitsch  M, Clinical outcomes of Estonian patients with multi-drug resistant versus drug-susceptible tuberculosis. Clin Infect Dis. 2001;32:37380. DOIPubMed
  19. Espinal  MA, Kim  SJ, Suarez  PG, Kam  KM, Khomenko  AG, Migliori  GB, Standard short-course chemotherapy for drug-resistant tuberculosis, treatment outcomes in 6 countries. JAMA. 2000;283:253745. DOIPubMed
  20. Raviglione  MC, Gupta  R, Dye  CM, Espinal  MA. The burden of drug-resistant tuberculosis and mechanisms for its control. Ann N Y Acad Sci. 2001;953:8897. DOIPubMed
  21. Farmer  P, Bayona  J, Becerra  J, Furin  J, Henry  C, Hiatt  H, The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis. 1998;2:86976.PubMed

Main Article

Page created: February 22, 2011
Page updated: February 22, 2011
Page reviewed: February 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external